Market Overview - The Hang Seng Index (HSI) closed at 26,513.11, down by 334.21 points or 1.24% [1] - The index reached a high of 26,812.73 and a low of 26,414.23 during the trading session [1] - The trading volume was 70.4034 million shares, with an average price of 26,613.48 [1] Major Blue-Chip Stocks Performance - HSBC Holdings closed at HKD 139.704, up by 0.51% compared to the previous close [2][3] - Tencent Holdings closed at HKD 552.190, down by 1.04% compared to the previous close [2][3] - Alibaba Group (W) closed at HKD 159.500, down by 0.93% [3] - AIA Group closed at HKD 90.700, up by 1.40% [3] - Xiaomi Group (W) closed at HKD 33.960, down by 1.85% [3] - Meituan (W) closed at HKD 92.150, down by 1.13% [3] - China Ping An closed at HKD 72.050, up by 1.05% [3] ADR Performance - Tencent's ADR (TCEHY) was priced at USD 552.190, reflecting a decrease of 1.04% compared to its Hong Kong counterpart [3] - Alibaba's ADR (BABA) was priced at USD 155.411, down by 2.56% compared to its Hong Kong counterpart [3] - HSBC's ADR (HSBC) was priced at USD 139.704, up by 0.51% compared to its Hong Kong counterpart [3]

Core Viewpoint - The company, BeiGene, is a leading global innovator in cancer treatment, focusing on developing innovative anti-tumor drugs to enhance accessibility and affordability for cancer patients [2]. Financial Performance - For the period from January to September 2025, BeiGene achieved a revenue of 27.595 billion yuan, representing a year-on-year growth of 44.21% [6]. - The net profit attributable to the parent company was 1.139 billion yuan, showing a significant year-on-year increase of 130.88% [6]. Market Activity - On February 3, BeiGene's stock rose by 1.64%, with a trading volume of 651 million yuan and a turnover rate of 2.08%, bringing the total market capitalization to 421.221 billion yuan [1]. - The stock has seen a net outflow of 17.2595 million yuan from major investors today, with a ranking of 145 out of 158 in the industry [3][4]. Shareholder Information - As of September 30, 2025, the number of shareholders for BeiGene increased to 36,200, a rise of 55.33% compared to the previous period [6]. - The average number of tradable shares per shareholder decreased by 35.79% to 3,195 shares [6]. Institutional Holdings - Among the top ten circulating shareholders, China Europe Medical Health Mixed A holds 4.6788 million shares, a decrease of 146,600 shares from the previous period [7]. - Hong Kong Central Clearing Limited is a new shareholder with 3.1565 million shares [7].

Core Viewpoint - The healthcare sector in A-shares is experiencing a significant rally, driven by AI healthcare and CXO concepts, with notable inflows into medical ETFs [1][8]. Group 1: ETF Performance - The largest medical ETF in A-shares (512170) saw an intraday increase of over 1%, recovering its annual line, with a net subscription of 2.633 billion yuan over the past 10 days as of February 2 [1][8]. - The medical ETF fund size reached 27 billion yuan, making it the largest in the market for medical ETFs [6][13]. Group 2: Individual Stock Movements - The Hong Kong medical ETF (159137) surged by 2%, ending a three-day decline, with Ark Health rising over 20% and BeiGene increasing by more than 4% [10]. - Ark Health raised approximately 144 million HKD through a placement of about 45.181 million shares, with 90% of the funds allocated to accelerate the development of an AI-driven chronic disease management platform [3][10]. Group 3: Industry Developments - Huawei Cloud launched the first section of its industry AI "Dream Factory" focused on smart healthcare, providing a collaborative pathology solution for grassroots hospitals [5][12]. - Institutions predict that by 2026, AI applications will transition from usable to highly effective, becoming a core theme in the AI industry, particularly in healthcare, finance, and education sectors [6][12].

Core Insights - The CDMO (Contract Development and Manufacturing Organization) business of multinational companies in China is experiencing significant decline, with many exiting the market entirely [1][8] - The Chinese CDMO market is growing rapidly, with a compound annual growth rate of 39.9% from 2018 to 2023, and is expected to reach 208.4 billion RMB by 2028 [16] Group 1: Multinational CDMO Operations in China - Multinational companies like Lonza, Thermo Fisher, and Merck have faced challenges in their CDMO operations in China, with many either closing facilities or selling them off [4][5][6] - Lonza's Guangzhou factory, which was operational for only three years, was sold to a local company due to insufficient orders [4] - Thermo Fisher's factory in Hangzhou is struggling with low order volumes, and its future remains uncertain [5][6] Group 2: Local CDMO Developments - Zhaoyan Biotech's new manufacturing base in Guangzhou, which focuses on large molecule CDMO, signifies a strategic move to enhance capacity and create a collaborative platform for biopharmaceutical innovation in Southeast Asia [3] - Local companies are increasingly building their own production capabilities, reducing reliance on foreign CDMO services [14] Group 3: Market Dynamics and Trends - The introduction of the MAH (Marketing Authorization Holder) system in 2019 has lowered production barriers, allowing more companies to utilize CDMO services [11] - Despite the advantages of a large workforce and lower costs, foreign CDMOs have struggled to establish a foothold in China due to high pricing models that do not align with local market conditions [12][13] - The efficiency and cost-effectiveness of Chinese CDMOs are becoming competitive with their foreign counterparts, leading to a shift in market dynamics [15][16]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2026年1月23 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二百四十六名承授人授 出涉及合共21,034股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 於2026年1月23日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二百 四十六名承授人合共21,034股美國存託股份受限制股份單位。該等受限制股份單 位相當於273,442股股份，約佔本公告之日公司發行股份總數的0.02%。 授出受限制股份單位詳情 受限制股份單位詳情如下： 1 授出日期： 2026年1月23日 承授人數目： 二百四十六名 已授出受限制股份單位涉及的 相關股份數目： 273,44 ...

Group 1 - The core issue raised by investors is the significant discrepancy in interest income and income tax between the US and A-share reports of the company, specifically highlighting a negative interest income of -15.8 million USD (approximately -110 million RMB) in the US market for 2021, compared to an interest income of 44.1 million RMB in the A-share annual report [1] - The company clarified that the financial statements for the US and A-share are prepared according to different accounting standards, namely US Generally Accepted Accounting Principles (GAAP) and Chinese Accounting Standards, and referred investors to the section on "Differences in Accounting Data under Domestic and Foreign Accounting Standards" in the A-share financial report for more details [1]

百济神州(06160)发布公告，于2026年1月23日，董事会薪酬委员会根据2016期权及激励计划的条款向二 百四十六名承授人授出涉及合共2.1万股美国存托股份的受限制股份单位。 ...

智通财经APP讯，百济神州(06160)发布公告，于2026年1月23 日，董事会薪酬委员会根据2016期权及激 励计划的条款向二百四十六名承授人授出涉及合共2.1万股美国存托股份的受限制股份单位。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2026年1月23 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二百四十六名承授人授 出涉及合共21,034股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 於2026年1月23日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二百 四十六名承授人合共21,034股美國存託股份受限制股份單位。該等受限制股份單 位相當於273,442股股份，約佔本公告之日公司發行股份總數的0.02%。 授出受限制股份單位詳情 受限制股份單位詳情如下： 1 授出日期： 2026年1月23日 承授人數目： 二百四十六名 已授出受限制股份單位涉及的 相關股份數目： 273,44 ...

Market Overview - The Hang Seng Index (HSI) closed at 27,742.89, down by 225.20 points or 0.81% as of January 29, 16:00 Eastern Time [1] - The index reached a high of 27,909.81 and a low of 27,419.65 during the trading session, with an average price of 27,664.73 [1] - The 52-week high for the index is 27,909.81, while the 52-week low is 19,335.70 [1] Blue-Chip Stocks Performance - Most large-cap stocks experienced declines, with HSBC Holdings closing at HKD 138.219, up 0.45% compared to the Hong Kong close [2] - Tencent Holdings closed at HKD 619.286, down 0.44% from the Hong Kong close [2] Individual Stock Movements - Tencent Holdings (00700) latest price is HKD 622.000, with a slight increase of 1.000 or 0.16% [3] - Alibaba Group (09988) latest price is HKD 173.300, down by 0.200 or 0.12% [3] - HSBC Holdings (00005) latest price is HKD 137.600, up by 0.100 or 0.07% [3] - China Construction Bank (00939) latest price is HKD 8.160, up by 0.130 or 1.62% [3] - AIA Group (01299) latest price is HKD 90.950, up by 2.100 or 2.36% [3] - Xiaomi Group (01810) latest price is HKD 36.620, up by 0.300 or 0.83% [3] - NetEase (099999) latest price is HKD 206.600, down by 5.400 or 2.55% [3] - Meituan (03690) latest price is HKD 98.600, up by 0.250 or 0.25% [3] - Industrial and Commercial Bank of China (01398) latest price is HKD 6.640, up by 0.050 or 0.76% [3] - Hong Kong Exchanges and Clearing (00388) latest price is HKD 444.200, up by 5.000 or 1.14% [3] - Ping An Insurance (02318) latest price is HKD 73.300, up by 2.350 or 3.31% [3] - Baidu Group (09888) latest price is HKD 155.500, down by 0.600 or 0.38% [3] - China Bank (03988) latest price is HKD 4.760, up by 0.090 or 1.93% [3] - BYD Company (01211) latest price is HKD 101.800, down by 1.000 or 0.97% [3] - JD.com (09618) latest price is HKD 114.600, down by 1.700 or 1.46% [3] - Ctrip Group (09961) latest price is HKD 482.200, down by 13.200 or 2.66% [3]